Full Press Release Details
COMMENTS ON CONSENT SOLICITATION RESULTS
Vieser and Holger Weis Elected to Board of Directors; Scott Tarriff Departs Board
December 16, 2020 - Ziopharm Oncology, Inc. (Nasdaq: ZIOP) ("Ziopharm" or the "Company"), today
issued a statement in connection with the consent solicitation (the "Consent Solicitation") initiated by WaterMill
Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, "WaterMill"). Based on the
consents received by the Company, Jaime Vieser and Holger Weis have been formally elected to the Ziopharm Board of Directors (the
"Board"), while Chairman Scott Tarriff will depart the Board effective immediately.
Company's statement is as follows:
sincerely thank our shareholders for all of the helpful feedback and constructive dialogue that they have shared with the Company
since our 2020 Annual Meeting. We welcome Messrs. Vieser and Weis as the newest members of Ziopharm's Board of Directors.
also wish to thank Scott Tarriff for his service as a member of the Board since 2015 and as Chairman since 2018. We wish him well
in the future. We continue to focus on achieving the high potential that our pipeline offers and delivering significant value
to both patients and shareholders."
full results of the Consent Solicitation will be disclosed via a Current Report on Form 8-K filing with the U.S. Securities and
Exchange Commission (the "SEC") in due course.
Ziopharm Oncology, Inc.
is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body's immune system to treat the
millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront
of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm's pipeline is built for commercially scalable,
cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled
IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and
strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more
information, please visit www.ziopharm.com.
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm management.
Forward-looking statements include all statements that are not historical facts, and can be identified by terms such as "anticipate,"
"believe," "contemplate," "continue," "could," "estimate," "expect,"
"hope," "intend," "may," "might," "objective," "ongoing,"
"plan," "potential," "predict," "project," "should," "target,"
"will," or "would" or similar expressions and the negatives of those terms. Any forward-looking statements
are based on management's current expectations of future events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
Such risks and uncertainties include, among others, the impact of the Consent Solicitation and other activities by WaterMill and/or
other investors, the risks and uncertainties disclosed in Ziopharm's most recent Quarterly Report on Form 10-Q for the quarter
ended September 30, 2020 as well as discussions of potential risks, uncertainties and other important factors in any subsequent
filings by Ziopharm with the SEC. All information in this press release is as of the date hereof, and Ziopharm undertakes no duty
to update the information, except as required by law.
EVP, Investor Relations and Corporate Communications
Kittredge, Andrew Cole and Zachary Tramonti